Literature DB >> 14734228

Methylation status of TP73 in meningiomas.

Jesus Lomas1, Cinthia Amiñoso, Pilar Gonzalez-Gomez, M Eva Alonso, Dolores Arjona, Isabel Lopez-Marin, Jose M de Campos, Alberto Isla, Jesus Vaquero, Manuel Gutierrez, Jose L Sarasa, M Josefa Bello, Juan A Rey.   

Abstract

Deletions at 1p are frequent in meningioma and represent a genetic marker associated with the genesis of atypical WHO grade II forms. Previous mutational analysis of TP73, a structurally and functionally TP53 homologous gene located at 1p36.33, failed to demonstrate a significant rate of sequence variations linked to gene inactivation in meningiomas with 1p loss. As an alternative, TP73 may be inactivated through aberrant 5' CpG island methylation, a primary mechanism participating in the inactivation of tumor suppressor genes during tumorigenesis. We determined the methylation status of the TP73 gene in a series of 60 meningiomas (33 grade I, 24 grade II, and 3 grade III samples), including tumors with deletion at 1p (n=30) and with intact 1p (n=30). Aberrant methylation was detected in 10 cases (33%) with 1p deletion and in 3 tumors (10%) with retention of alleles at this chromosome arm. The distribution of the 13 cases of methylation according to malignancy grade was 7 grade I, 5 grade II, and 1 grade III tumor. Accordingly, although TP73 aberrant methylation was more frequent in meningiomas with 1p deletion (P<0.05), no association with the grade of malignancy could be established. These findings, together with the previously reported increased TP73 expression in malignant meningiomas suggest that opposing functions of this gene may characterize distinct subsets of tumors: suppressed or reduced expression as a result of CpG methylation in some grade I-grade II tumors, and enhanced expression in some more malignant forms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734228     DOI: 10.1016/s0165-4608(03)00244-9

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  6 in total

1.  Molecular progression in unusual recurrent non-pediatric intracranial clear cell meningioma.

Authors:  B Domingo-Arrué; R Gil-Benso; J Megías; L Navarro; T San-Miguel; L Muñoz-Hidalgo; C López-Ginés; M Cerdá-Nicolás
Journal:  Curr Oncol       Date:  2017-06-27       Impact factor: 3.677

2.  High-throughput DNA methylation profiling using universal bead arrays.

Authors:  Marina Bibikova; Zhenwu Lin; Lixin Zhou; Eugene Chudin; Eliza Wickham Garcia; Bonnie Wu; Dennis Doucet; Neal J Thomas; Yunhua Wang; Ekkehard Vollmer; Torsten Goldmann; Carola Seifart; Wei Jiang; David L Barker; Mark S Chee; Joanna Floros; Jian-Bing Fan
Journal:  Genome Res       Date:  2006-01-31       Impact factor: 9.043

3.  Methylation-specific multiplex ligation-dependent probe amplification identifies promoter methylation events associated with survival in glioblastoma.

Authors:  K L Rankeillor; D A Cairns; C Loughrey; S C Short; P Chumas; A Ismail; A Chakrabarty; S E Lawler; P Roberts
Journal:  J Neurooncol       Date:  2014-02-20       Impact factor: 4.130

4.  Early malignant transformation of a petroclival meningothelial meningioma.

Authors:  Shigeo Ohba; Kazunari Yoshida; Yuichi Hirose; Eiji Ikeda; Takeshi Kawase
Journal:  Neurosurg Rev       Date:  2009-06-17       Impact factor: 3.042

5.  Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific.

Authors:  Peter Jun; Chibo Hong; Anita Lal; Judith M Wong; Michael W McDermott; Andrew W Bollen; Christoph Plass; William A Held; Dominic J Smiraglia; Joseph F Costello
Journal:  Neuro Oncol       Date:  2008-11-11       Impact factor: 12.300

6.  Gene expression analysis of aberrant signaling pathways in meningiomas.

Authors:  Miguel Torres-Martín; Victor Martinez-Glez; Carolina Peña-Granero; Alberto Isla; Luis Lassaletta; Jose M DE Campos; Giovanny R Pinto; Rommel R Burbano; Bárbara Meléndez; Javier S Castresana; Juan A Rey
Journal:  Oncol Lett       Date:  2013-05-23       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.